Quantum Technologies Strategic Imperatives for Health and Healthcare Leaders 2025

From drug discovery to manufacturing, a growing number of organizations are experimenting with quantum technologies across the biomedical value chain to create business value. Most efforts remain in early stages; however, select examples help illustrate both the potential and the challenges involved in applying quantum solutions to health R&D. Mapping use case maturity and benefits across the value chain TABLE 6 Value chain stage Quantum use cases Maturity Business benefits Target identification mRNA secondary structure predictionPrototype (3–5 years) –Cost and time savings –New revenue streams Simulation and measurementMolecular dynamics simulation Prototype (3–5 years) –Cost and time savings –New revenue streams Protein folding prediction Experimental (6–10 years) Photodynamic property modelling Experimental (6–10 years) Candidate screening High-throughput ligand-protein interaction simulationPrototype (3–5 years) –Cost and time savings –Enhanced clinical success Bio-silico peptide screening Prototype (3–5 years) Preclinical modelling Predictive toxicology modelling Theoretical (10+ years) –Enhanced clinical success –Cost and time savings Biological response simulation Theoretical (10+ years) Clinical trials Cohort selection optimization Prototype (3–5 years) –Cost and time savings –Enhanced clinical success Biomanufacturing optimizationQuantum photonic particle sensing for inline bioprocess controlCommercial (0–2 years) –New revenue streams –Cost and time savings Quality assurance Quantum diamond sensors for high- throughput magnetic bioassaysCommercial (0–2 years) –Increased revenue –Cost and time savings Source: World Economic Forum and Accenture.2.2 Quantum value chain for creators Quantum Technologies: Strategic Imperatives for Health and Healthcare Leaders 13